Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 23, 1998

View Archived Issues

Alexion: Q4 1998 highlights

Xenotransplanted human dopaminergic cells improve motor deficits in MPTP-treated monkeys

Roche: Q3 1998 highlights

Shionogi: Annual Report 1998

Simulect gets the go-ahead from the European Commission

Potent antitumor activity, low toxicity observed in in vitro studies of aplidine

SR-121787: the most potent fibrinogen antagonist reported to date

Potent GABA-B antagonists described for CNS disorders by Novartis

Monosaccharide conjugates of pyrimethamine and other therapeutic agents patented

New series of antiischemic/antiarrhythmic compounds developed at HMR

New compounds from Astra for pain, GI disorders and spinal injuries

Potent new PDE5 inhibitor with potential clinical utility

Antiulcer angucycline compound isolated from Streptomyces

Fournier characterizes potent and selective human bradykinin B2 antagonist in vitro

Takeda discontinues further development of osteoporosis drug

Antibacterial ointment preparation for periodontitis will be codeveloped by Toyama and Showa

Efficacy and safety demonstrated for rasagiline as adjunct to levodopa in PD

Botulinum toxin type F useful in type A-resistant patients with dystonia

Effects of DX-9065a on platelet activation reported at international congress

Platelet collagen receptors targeted for development of new antiplatelet therapies

Phase III trial of Nutropin Depot successfully completed; NDA filing slated for 1999

Tacalcitol lotion equivalent to ointment in animal study

Roche granted additional exclusivity for Versed from FDA

Potent new antibiotic isolated from soil microorganism undergoes further evaluation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...